Abstracts Clinical Lymphoma, Myeloma & Leukemia September 2023 S316 chemotherapy regimen. In Latin America and Colombia, there are no studies evaluating the possible associations of CGA with outcomes in patients with AML. Objective: To evaluate the association between CGA and clinical outcomes in patients with AML in a university hospital in Colombia. Design: Retrospective cohort study conducted between June 1, 2013, and December 31, 2021. All patients were followed for at least one year after AML diagnosis. Setting: Referral center caring for adult patients with AML. Patients or Other Participants: Patients aged 60 years or older (60+) with a diagnosis of AML and CGA were included. Interventions: Patients in the study underwent CGA. Univariate and bivariate analyses were performed to describe the study population and determine the possible association of the CGA scales with outcome measures. Main Outcome Measures: Overall survival, event-free survival, toxicity, and complete remission after induction chemotherapy. Results: Seventy-seven patients 60+ were included. The median age was 71 years (IQR:64–79), 53.2% were men, and 55.8% (n=43) had ECOG < 2. In line with the Frail Scale, 54.5% (n=42) and 32.5% (n=25%) were pre-frail and frail, respectively. Pre-frailty and frailty according to the Frail Scale were associated with shorter overall survival (HR 1.6, 95%CI 1.05-2.55). Mild dependence according to the Lawton scale reduced the probability of complete remission after induction chemotherapy by 56% (RR 0.4, 95%CI 0.20-0.96). CGA was not associated with event-free survival or toxicity. Conclusions: Frailty or pre-frailty according to the Frail scale in adults 60+ with a diagnosis of AML was associated with a shorter overall survival at one year. Furthermore, this is the first analytical observational study in the literature to describe a statistically significant association between the Frail score and overall survival in elderly patients with a diagnosis of AML. Keywords: AML, acute myeloid leukemia, comprehensive geriatric assessment, Latin America AML-607 Acute Myeloid Leukemia During Pregnancy: A Very Rare Presentation With Bilateral Breast Masses Alyaa R. Elsergany MD1, Sameh Shamaa MD1, Maha Ibrahim Ismaeel MD1, Mohamed A. Ibrahim MD1, Asmaa Sherif MScs1, Asmaa Fawzy MScs1, Sara Atwa MScs1, Dina Fathy MScs1, Dina Farahat MScs1, Nada Foad M.B.B.CH1, Hend Noaman M.B.B.CH1, Sara Morgan MScs1, Ibrahim Zahran M.B.B.CH1, Shrouk Ahmed M.B.B.CH1, Ahmed Elbialy MScs1, Tasneem Mohamed M.B.B.CH1, Marium Elmoataesm M.B.B.CH1, Alaa Abd Elrahman M.B.B.CH1, Hager Salem M.B.B.CH1, Eman Eid MD1, Ayaa Waheed MScs1, Basma Atef MD2, Rana Mohamed M.B.B.CH1, Khaled Refaat Zalatah MD3, Dina El tantawy MD3, Madona Ibrahim Wiliam MScs3, Dalia A. Salem MD4, Doaa A. Eladl MD4 1Medical oncology unit,Internal Medicine Department,Mansoura Faculty Of Medicine, Mansoura, Egypt. 2Clinical hematology unit,Internal Medicine Department,Mansoura Faculty Of Medicine, Mansoura, Egypt. 3Pathology Department, Mansoura Faculty Of Medicine, Mansoura, Egypt. 4Clinical Pathology Department, Mansoura Faculty Of Medicine, Mansoura, Egypt Context: Acute myeloid leukemia (AML) comprises a heterogeneous group of aggressive blood cell cancers that arise from clonal expansion of malignant hematopoietic precursor cells in the bone marrow. Patients with AML generally present with symptoms related to complications of pancytopenia (eg, anemia, neutropenia, and thrombocytopenia). Objective: The case herein is a very rare presentation of AML. Design: A case report of a 23-year-old Egyptian female patient, pregnant at 6th months, who presented in 2022 with bilateral malignant looking breast masses. Setting: Oncology Center Mansoura University. Patient: Our patient presented with bilateral breast masses which increased in size during her 6th month of pregnancy, so she sought medical advice. Sonographic evaluation revealed a multiple bilateral breast masses with multiple suspicious axillary LNs. The patient underwent tru-cut biopsy of mass which revealed acute leukemic infiltrate confirmed by IHC. Patient suddenly developed paraparesis and presented to our ER unit. MRI lumbosacral reveled and intramural extra medullary lesion of abnormal SI extending opposite D10 down to D12, compressing/displacing distal cord and conus anteriorly 1.5X1.5X7 cm. CBC analysis revealed white blood cell count of 55 k/µL, normocytic normochromic anemia with 11.9 g/dL, platelets count of 52 k/µL. Bone marrow aspiration revealed a normocellular 63% blasts. Flowcytometry showed AML (M2). Cytogenetics were negative for t(8;21) and also negative for inv.16. Interventions: The patient underwent laminectomy. Postoperative pathology showed leukemia infiltrate. Gynecological consultation was done then patient start standard induction with 3 days anthracyclin with 7 days cytrabine followed by bone marrow re-evaluation that revealed complete remission (normocellular 2% blasts ). The patient then underwent cesarean delivery of a full term viable baby. She started consolidation (HDA ) for 4 cycles and HLA matching was done. MRI lumbosacral and breasts re-evaluation were negative. The patient is still in complete remission till now, Conclusions: AML may be presented initially with extra medullary infiltrate like breast masses which mimics breast carcinoma Keywords: AML, pregnancy, cytogenetics, flowcytometry, complete remission AML-643 Precision‑Engineered Cell Therapy Orca‑T Demonstrates High Relapse‑Free Survival at 1 Year While Reducing Graft‑Versus‑Host Disease (GvHD) and Toxicity Amandeep Salhotra MD1, Caspian Oliai MD, MS2, RasmusT. Hoeg MD3, Arpita Gandhi MD4, Lori Muffly MD, MS5, Samer A. Srour MB ChB, MS6, Edmund Waller MD, PhD7, Robert Lowsky MD5, Sagar Patel MD8, Bhagirathbhai Dholaria M.B.B.S.9, Jeremy Pantin MD10, Anna Pavlova MD, PhD11, Nathaniel Fernhoff PhD11, James Scott McClellan MD, PhD11, Mehrdad Abedi MD3, Robert Negrin MD5, Everett Meyer MD, PhD5 1City of Hope National Medical Center, Duarte, USA. 2UCLA Jonsson Comprehensive Cancer Center, Los Angeles, USA. 3University of California, Davis, Sacramento, USA. 4Oregon Health Sciences University, Portland, USA. 5Stanford University, Stanford, USA. 6MD
RkJQdWJsaXNoZXIy MTk3NTQxMg==